EUVIMEDEUVIMED entdecken
Open Access

Development and Optimization of a Bladder Cancer Algorithm Using SEER-Medicare Claims Data

John L Gore iD, Phoebe Wright iD, Vanessa Shih, Nancy N Chang iD, Sina Noshad, Gabriel G Rey, Steven Wang, Sujata Narayanan

JCO Clinical Cancer Informatics · 2024

DOI: 10.1200/cci.24.00073 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Clinical Cancer Informatics, 2024. Verfasst von John L Gore und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of Washington, Seattle, WA. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Algorithms, SEER Program, Medicare. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Categorizing patients with cancer by their disease stage can be an important tool when conducting administrative claims-based studies. As claims databases frequently do not capture this information, algorithms are increasingly used to define disease stage. To our knowledge, to date, no study has used an algorithm to categorize patients with bladder cancer (BC) by disease stage (non–muscle-invasive BC [NMIBC], muscle-invasive BC [MIBC], or locally advanced/metastatic urothelial carcinoma [la/mUC]) in a US-based health care claims database. METHODS A claims-based algorithm was developed to categorize patients by disease stage on the basis of the administrative claims portion of the SEER-Medicare linked data. The algorithm was validated against a reference SEER registry, and the algorithm's parameters were iteratively modified to improve its performance. Patients were included if they had an initial diagnosis of BC between January 2016 and December 2017 recorded in SEER registry data. Medicare claims data were available for these patients until December 31, 2019. The algorithm was evaluated by assessing percentage agreement, Cohen's kappa (κ), specificity, positive predictive value (PPV), and negative predictive value (NPV) against the SEER categorization. RESULTS A total of 15,484 patients with SEER-confirmed BC were included: 10,991 (71.0%) with NMIBC, 3,645 (23.5%) with MIBC, and 848 (5.5%) with la/mUC. After multiple rounds of algorithm optimization, the final algorithm had an agreement of 82.5% with SEER, with a κ of 0.58, a PPV of 87.0% for NMIBC, and 76.8% for MIBC and a high NPV for la/mUC of 98.0%. CONCLUSION This claims-based algorithm could be a useful approach for researchers conducting claims-based studies categorizing patients with BC at diagnosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsAlgorithmsSEER ProgramMedicareNeoplasm StagingHumansUnited StatesMaleAgedFemaleAged, 80 and overDatabases, FactualInsurance Claim Review

Autor:innen und Institutionen

  • University of Washington, Seattle, WA.
  • Pfizer Inc, Bothell, WA.
  • Genesis Research Group, Hoboken, NJ.

ORCID-Profile: John L Gore, Phoebe Wright, Nancy N Chang

Zitieren

APA

Gore, J. L., Wright, P., Shih, V., Chang, N. N., Noshad, S., Rey, G. G., Wang, S., & Narayanan, S. (2024). Development and Optimization of a Bladder Cancer Algorithm Using SEER-Medicare Claims Data. JCO Clinical Cancer Informatics. https://doi.org/10.1200/cci.24.00073

Vancouver

Gore JL, Wright P, Shih V, Chang NN, Noshad S, Rey GG, et al. Development and Optimization of a Bladder Cancer Algorithm Using SEER-Medicare Claims Data. JCO Clinical Cancer Informatics. 2024. doi:10.1200/cci.24.00073

BibTeX
@article{Gore2024,
  author = {Gore, John L and Wright, Phoebe and Shih, Vanessa and Chang, Nancy N and Noshad, Sina and Rey, Gabriel G and Wang, Steven and Narayanan, Sujata},
  title = {Development and Optimization of a Bladder Cancer Algorithm Using SEER-Medicare Claims Data},
  journal = {JCO Clinical Cancer Informatics},
  year = {2024},
  doi = {10.1200/cci.24.00073}
}
Kostenlos starten →